论文部分内容阅读
Objective: Combined overall survival(OS) analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor(EGFR) exon 19 deletions(Del19) would benefit from first-line second generation EGFR tyrosine kinase inhibitors(